已核实 DOI PubMed 相关产品: 3

Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α

Journal 2019 · IF 4.833 · 发表于 2019 年 12 月 16 日
作者: Yuxuan Dai,Na Yue,Junni Gong,Chunxia Liu,Qifei Li,Jiaqi Zhou,Wenlong Huang,Hai Qian
阅读全文 在 PubMed 查看

摘要

Proteolysis-targeting chimera (PROTAC) could selectively degrade target protein and may become a promising strategy for treating estrogen receptor α (ERα) positive breast cancers. Here, we designed penetrated peptide-based PROTACs by constructing an N-terminal lactam cyclic to improve proteolytic stability and cell penetration. We used a lactam cyclic peptide as ERα binding ligand , 6-aminocaproic acid as a linker, and a hydroxylated pentapeptide structure for recruiting E3 ligase to obtain heterobifunctional compounds. The resulting optimized compound I-6 selectively recruited ERα to the E3 ligase complex for promoting the degradation of ERα. Compound I-6 possessed strong effect on MCF-7 cell toxicity (IC 50 ∼9.7 μM) and significantly enhanced activities in inducing ERα degradation. Meanwhile, I-6 performed much stronger potency in inhibition of tumors growth than tamoxifen . This work is a successful template to construct PROTACs based on cell-permeable peptides, which could extend the chemical space of PROTACs.

本研究中使用的阿拉丁产品

3 款产品在本文中被引用